5002572026-04-012026-06-305002572026-06-305002572026-04-012026-06-30in-capmkt:OtherExpenses1Member5002572026-04-012026-06-30in-capmkt:OtherExpenses2Member5002572026-04-012026-06-30in-capmkt:ReportableSegments1Member5002572026-04-012026-06-30in-capmkt:ReportableSegments2Member5002572026-04-012026-06-30in-capmkt:ReportableSegments3Member5002572026-04-012026-06-30in-capmkt:ReportableSegments1Member5002572026-04-012026-06-30in-capmkt:ReportableSegments2Member5002572026-04-012026-06-30in-capmkt:ReportableSegments3Member5002572026-04-012026-06-30in-capmkt:ReportableSegments1Member5002572026-06-30in-capmkt:ReportableSegments1Member5002572026-04-012026-06-30in-capmkt:ReportableSegments2Member5002572026-06-30in-capmkt:ReportableSegments2Member5002572026-04-012026-06-30in-capmkt:ReportableSegments3Member5002572026-06-30in-capmkt:ReportableSegments3Member5002572026-04-012026-06-30in-capmkt:ReportableSegments1Member5002572026-06-30in-capmkt:ReportableSegments1Member5002572026-04-012026-06-30in-capmkt:ReportableSegments2Member5002572026-06-30in-capmkt:ReportableSegments2Member5002572026-04-012026-06-30in-capmkt:ReportableSegments3Member5002572026-06-30in-capmkt:ReportableSegments3Member5002572026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15002572026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2026-04-012027-03-312026-08-062026-07-22INRMillionsQuarterlyFirst quarterMulti segment2026-08-0616:30:002026-08-0621:40:00Not applicable2026-04-012026-06-30UnauditedConsolidated82768900000130320000084072100000131166000008422700000-64690000013830000000109640000045285000002355100000063898300000201738000000201738000009843900000-38401000006003800000014170000000000-200000141698000003551000001452490000014150000000198000001451134300013557000914500000230.9530.890030.9530.891. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. <br /> 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. - Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquimica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A, Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A., Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India, Lupin Manufacturing Solutions Limited - India, Medisol S.A.S. - France, Lupin Lanka (Private) Ltd. - Sri Lanka, Lupin NZ Ltd. - New Zealand, Lupinlife Consumer Healthcare Limited - India, Renascience Pharma Limited - U.K. (w.e.f. April 02, 2025), VISUfarma B.V. - Netherlands (w.e.f. April 01, 2026), VISUfarma UK Limited - U.K. (w.e.f. April 01, 2026), VISUfarma SPA - Italy (w.e.f. April 01, 2026), IRIS Bidco SAS - France (w.e.f. April 01, 2026), IRIS BidCo Srl - Italy (w.e.f. April 01, 2026), VISUfarma Espana SL, Spain (w.e.f. April 01, 2026), Laboratorios Nicox SLU, Spain (w.e.f. April 01, 2026), Lupin (Thailand) Limited, Thailand (w.e.f April 17, 2026) and a joint venture, YL Biologics Limited - Japan. <br /> 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures". <br /> 4. During the quarter ended June 30, 2026, 53,425 equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by Rs. 0.1 million and securities premium account by Rs. 76.9 million. <br /> 5. During the quarter ended June 30, 2026, acquisition of wholly owned subsidiary VISUfarma B.V., Netherlands was concluded by Nanomi B.V., Netherlands on April 01, 2026, with total consideration of Rs. 20,902.7 million (Euro 192.8 million). Fair value of intangibles acquired Rs. 15,971.1 million, deferred tax liability Rs. 3,992.8 million, Goodwill Rs. 6,030.2 million has been provisionally accounted based on report of independent valuer. The acquisition related costs are accounted in "Other expenses". <br /> 6. Exceptional items <br /> a. The Group is exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and possible violation of federal and state antitrust laws. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended March 31, 2026; the Group has based on best estimate, created a provision, of Rs. 1,323.1 million (USD 15.8 million), resulting in cumulative provision of Rs. 5,816.9 million (USD 65.8 million) at year ended March 31, 2026 related to antitrust litigation matters. In April 2026, Lupin Pharmaceuticals, Inc., U.S.A., a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matters for an amount of Rs. 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. The remaining provision continues to be carried by the Group towards future settlements related to similar cases. <br /> b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. In respect of the same, Lupin Pharmaceuticals, Inc., U.S.A. paid Rs. 8,475.5 million (USD 90.0 million), which includes Rs. 7,110.8 million (USD 75.0 million) as Prepaid Option and Rs. 1,364.7 million (USD 15.0 million) as one-time payment towards the settlement. During the year ended March 31, 2026, the Group has expensed out Rs. 1,364.7 million (USD 15.0 million) and has capitalised the balance amount towards Prepaid Option. <br /> c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 512.2 million during the year ended March 31, 2026. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <br /> d. During the year ended March 31, 2026, the Group entered into a settlement agreement with an income of Rs. 873.7 million (USD 10.0 million). <br /> e. During the year ended March 31, 2026, the Group has received an arbitration award, consequently accounted an income of Rs. 603.2 million (USD 6.9 million) and a reversal of expense provision of Rs. 611.6 million (USD 7.0 million). <br /> 7. During the quarter ended June 30, 2025, the Company through its wholly owned step-down subsidiary, Lupin Healthcare (UK) Limited, U.K., acquired 100% equity share capital of Renascience Pharma Limited, U.K., for a consideration of Rs. 1,361.6 million (GBP 12.3 million). Fair value of intangibles acquired Rs. 1,239.4 million, deferred tax liability Rs. 309.8 million, Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. The acquisition related costs are accounted in "Other expenses". <br /> 8. During the quarter and year ended March 31, 2026, the Group has recognised an impairment charge of Rs. 879.1 milion and Rs. 1,130.1 milion respectively related to certain capital work-in-progress, intangible assets and intangible assets under development. <br /> 9. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the previous full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2025. The year-to-date figures up to the third quarter ended December 31, 2025 were only subject to Limited Review and not audited.Other expenses23412000000Net loss / (gain) on foreign currency transactions139000000a) Pharmaceuticals82343540000b) Others430270000Less: Inter segment082773810000490000082768910000a) Pharmaceuticals20605830000b) Others-432030000Less: Inter segment0201738000000020173800000a) Pharmaceuticals406032960000b) Others2354630000Less: Inter segment-2165100004081710800000408171080000a) Pharmaceuticals167384120000b) Others1194770000Less: Inter segment-2165900001683623000000168362300000Remeasurements of Defined Benefit Liability-800000-800000-1100000The effective portion of gain & losses on hedging instruments in a cash flow hedge463100000Exchange differences in translating the financial statements of foreign operations58600000521700000166900000355100000